Cargando…

Intravesical Injection of Botulinum Toxin Type A in Patients with Refractory Overactive Bladder—Results between Young and Elderly Populations, and Factors Associated with Unfavorable Outcomes

Intravesical botulinum toxin type A (BoNT-A) injection has been recognized as the standard treatment for refractory overactive bladder (OAB). However, its therapeutic efficacy and safety have not been thoroughly reviewed in elderly patients. This study aims to provide treatment outcomes for patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ou, Yin-Chien, Kao, Yao-Lin, Ho, Yi-Hui, Wu, Kuan-Yu, Kuo, Hann-Chorng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967532/ https://www.ncbi.nlm.nih.gov/pubmed/36828410 http://dx.doi.org/10.3390/toxins15020095

Ejemplares similares

Efficacy of Intravesical Botulinum Toxin A Injection in the Treatment of Refractory Overactive Bladder in Children
por: Fan, Yu-Hua, et al.
Publicado: (2023)

The clinical application of intravesical botulinum toxin A injection in patients with overactive bladder and interstitial cystitis
por: Jiang, Yuan-Hong, et al.
Publicado: (2022)

Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis
por: Chen, Jing-Liang, et al.
Publicado: (2020)

Practical Aspects of Botulinum Toxin-A Treatment in Patients With Overactive Bladder Syndrome
por: Liao, Chun-Hou, et al.
Publicado: (2015)

Intravesical Injection of Botulinum Toxin Type A in Men without Bladder Outlet Obstruction and Post-Deobstructive Prostate Surgery
por: Lee, Hsiang-Ying, et al.
Publicado: (2023)

A comparative study between sacral neuromodulation and intravesical botulinum toxin injection for patients with refractory overactive bladder
por: Al-Azzawi, Issam S., et al.
Publicado: (2020)

Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome
por: Hsiao, Sheng-Mou, et al.
Publicado: (2016)

Treatment Outcomes of Intravesical Botulinum Toxin A Injections on Patients with Interstitial Cystitis/Bladder Pain Syndrome
por: Yu, Wan-Ru, et al.
Publicado: (2022)

Novel Applications of Non-Invasive Intravesical Botulinum Toxin a Delivery in the Treatment of Functional Bladder Disorders
por: Jhang, Jia-Fong, et al.
Publicado: (2021)

Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection on Elderly Patients with Chronic Central Nervous System Lesions and Overactive Bladder
por: Jiang, Yuan-Hong, et al.
Publicado: (2014)

Is there any Relationship Between Bladder Trabeculation and Efficacy and Safety of Intravesical Botulinum Toxin A Injection in Refractory Idiopathic Overactive Bladder Women?
por: Zargham, Mahtab, et al.
Publicado: (2017)

The Pharmacological Mechanism of Diabetes Mellitus-Associated Overactive Bladder and Its Treatment with Botulinum Toxin A
por: Wang, Chung-Cheng, et al.
Publicado: (2020)

Learning Curve of Botulinum Toxin Bladder Injection for the Treatment of Refractory Overactive Bladder
por: Barba, Marta, et al.
Publicado: (2022)

Adverse Events of Intravesical OnabotulinumtoxinA Injection between Patients with Overactive Bladder and Interstitial Cystitis—Different Mechanisms of Action of Botox on Bladder Dysfunction?
por: Kuo, Yuh-Chen, et al.
Publicado: (2016)

Will repeated botulinum toxin A improve detrusor overactivity and bladder compliance in patients with chronic spinal cord injury?
por: Chen, Sheng-Fu, et al.
Publicado: (2020)

Predictive Factors for a Satisfactory Treatment Outcome with Intravesical Botulinum Toxin A Injection in Patients with Interstitial Cystitis/Bladder Pain Syndrome
por: Wang, Hsiu-Jen, et al.
Publicado: (2019)

Comparison of the Clinical Efficacy and Adverse Events between Intravesical Injections of Platelet-Rich Plasma and Botulinum Toxin A for the Treatment of Interstitial Cystitis Refractory to Conventional Treatment
por: Jhang, Jia-Fong, et al.
Publicado: (2023)

Urodynamic prognostic factors for large post-void residual urine volume after intravesical injection of onabotulinumtoxinA for overactive bladder
por: Hsiao, Sheng-Mou, et al.
Publicado: (2017)

The Therapeutic Effects and Pathophysiology of Botulinum Toxin A on Voiding Dysfunction Due to Urethral Sphincter Dysfunction
por: Kao, Yao-Lin, et al.
Publicado: (2019)

Therapeutic Efficacy of Urethral Sphincteric Botulinum Toxin Injections for Female Sphincter Dysfunctions and a Search for Predictive Factors
por: Ou, Yin-Chien, et al.
Publicado: (2021)

Botulinum toxin A for the Treatment of Overactive Bladder
por: Hsieh, Po-Fan, et al.
Publicado: (2016)

Botulinum Toxin A Injection for Autonomic Dysreflexia—Detrusor Injection or Urethral Sphincter Injection?
por: Chow, Po-Ming, et al.
Publicado: (2023)

Liposome-Encapsulated Botulinum Toxin A in Treatment of Functional Bladder Disorders
por: Hung, Fan-Ching, et al.
Publicado: (2022)

Individualizing medical treatment of overactive bladder
por: Kuo, Hann-Chorng
Publicado: (2018)

Therapeutic Effects of Botulinum Toxin A, via Urethral Sphincter Injection on Voiding Dysfunction Due to Different Bladder and Urethral Sphincter Dysfunctions
por: Lee, Yu-Khun, et al.
Publicado: (2019)

Presence of Cleaved Synaptosomal-Associated Protein-25 and Decrease of Purinergic Receptors P2X3 in the Bladder Urothelium Influence Efficacy of Botulinum Toxin Treatment for Overactive Bladder Syndrome
por: Liu, Hsin-Tzu, et al.
Publicado: (2015)

Comparative study of different combinations of mirabegron and antimuscarinics in treatment for overactive bladder syndrome in elderly patients
por: Kuo, Yuh-Chen, et al.
Publicado: (2021)

Practical points in the medical treatment of overactive bladder and nocturia in the elderly
por: Chen, Jing-Liang, et al.
Publicado: (2016)

Deterioration of bladder compliance after botulinum toxin A injection and discontinuation of medication for overactive bladder
por: Wada, Naoki, et al.
Publicado: (2022)

Low-Energy Shock Wave Plus Intravesical Instillation of Botulinum Toxin A for Interstitial Cystitis/Bladder Pain Syndrome: Pathophysiology and Preliminary Result of a Novel Minimally Invasive Treatment
por: Jiang, Yuan-Hong, et al.
Publicado: (2022)

Clinical Efficacy and Changes of Urothelial Dysfunction after Repeated Detrusor Botulinum Toxin A Injections in Chronic Spinal Cord-Injured Bladder
por: Chen, Sheng-Fu, et al.
Publicado: (2016)

The use of botulinum toxin for the treatment of overactive bladder syndrome
por: Orasanu, Bogdan, et al.
Publicado: (2013)

Therapeutic Effect of Botulinum Toxin A on Sensory Bladder Disorders—From Bench to Bedside
por: Jiang, Yuan-Hong, et al.
Publicado: (2020)

Botulinum Toxin Brings a Light to the Shadow of Functional Urology
por: Kuo, Hann-Chorng
Publicado: (2023)

Increased Serum Adipokines Implicate Chronic Inflammation in the Pathogenesis of Overactive Bladder Syndrome Refractory to Antimuscarinic Therapy
por: Liu, Hsin-Tzu, et al.
Publicado: (2013)

Predictors of Response to Intradetrusor Botulinum Toxin-A Injections in Patients with Idiopathic Overactive Bladder
por: Cohen, Brian L., et al.
Publicado: (2009)

Delivery of intravesical botulinum toxin A using low-energy shockwaves in the treatment of overactive bladder: A preliminary clinical study
por: Nageib, Mohammed, et al.
Publicado: (2019)

Intradetrusor botulinum toxin type A in refractory overactive bladder: A potential future treatment
por: Mahajan, Rajiv, et al.
Publicado: (2011)

Effect of Botulinum Toxin A on Bladder Pain—Molecular Evidence and Animal Studies
por: Yeh, Ting-Chun, et al.
Publicado: (2020)

Emerging treatments for overactive bladder: clinical potential of botulinum toxins
por: Tincello, Douglas G, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_uek2ipmcb2065aphq7latnqqkc